Mesoblast Ltd. (MESO) Upgraded to Buy by Zacks Investment Research
Mesoblast Ltd. (NASDAQ:MESO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm currently has a $5.25 target price on the stock. Zacks Investment Research’s price target would suggest a potential upside of 13.39% from the company’s previous close.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Mesoblast (NASDAQ:MESO) opened at 4.63 on Wednesday. Mesoblast has a 12-month low of $3.50 and a 12-month high of $10.89. The stock has a 50 day moving average of $0.00 and a 200-day moving average of $0.00.
COPYRIGHT VIOLATION NOTICE: “Mesoblast Ltd. (MESO) Upgraded to Buy by Zacks Investment Research” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international trademark and copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/30/mesoblast-ltd-meso-upgraded-to-buy-by-zacks-investment-research.html.
A number of large investors have recently modified their holdings of MESO. Penbrook Management LLC bought a new stake in shares of Mesoblast during the third quarter valued at approximately $134,000. Citigroup Inc. raised its stake in Mesoblast by 659,900.0% in the second quarter. Citigroup Inc. now owns 33,000 shares of the company’s stock worth $131,000 after buying an additional 32,995 shares during the last quarter. Finally, Princeton Capital Management Inc. raised its stake in Mesoblast by 135.4% in the second quarter. Princeton Capital Management Inc. now owns 109,382 shares of the company’s stock worth $433,000 after buying an additional 62,915 shares during the last quarter. 3.25% of the stock is owned by institutional investors.
Mesoblast Company Profile
Receive News & Stock Ratings for Mesoblast Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Ltd. and related stocks with our FREE daily email newsletter.